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G protein-coupled receptors (GPCRs) are transmembrane proteins that modulate physiology across diverse 
tissues in response to extracellular signals. GPCR signalling can differ due to variation in the sequence (e.g. 
polymorphisms) or in the expression of receptors in different tissues. The resulting differences in response are 
an important source of physiological signalling bias. An underexplored source of such bias is the generation of 
functionally diverse GPCR isoforms that can have distinct patterns of expression in human tissues. Here, we 
report the findings from a comprehensive study, integrating data from human tissue-level transcriptomes, GPCR 
sequences and structures, functional annotations, proteomics, single-cell RNA sequencing, population-wide 
genetic association studies, and pharmacological experiments. Our results show how a single GPCR gene can 
diversify into multiple isoforms with distinct structural and signalling properties, and how unique combinations 
of these isoforms can be expressed in different human tissues, contributing to differences in physiological 
signalling. Based on their structural changes and expression patterns, some of the detected isoforms may also 
influence drug response and represent new drug targets with improved tissue selectivity. Our findings highlight 
the need to move from a canonical to a context-specific view of GPCR signalling, in which one considers how 
the combinatorial expression of receptor isoforms in a specific system (i.e. a particular cell type, tissue, or 
organism) collectively impacts receptor signalling. These observations pave the way for understanding the 
impact of isoform variation on GPCR signalling response and have implications for exploiting such variation as 










G protein-coupled receptors (GPCRs) are a diverse family of transmembrane receptors that are widely expressed 
across human tissues. They govern multiple physiological responses by binding to extracellular ligands and 
transducing their signal to a variety of intracellular coupling partners. Our understanding of GPCRs as 
modulators of human physiology has been complicated by the phenomenon of signalling bias, which results in 
variation in downstream responses due to the differential coupling of receptors with their associated intracellular 
signalling partners1,2. For instance, comparing receptor activation by endogenous and non-endogenous ligands, 
or in different systems such as cell types, tissues or organisms (i.e., in diverse cellular and physiological 
contexts), has revealed differences in pharmacological responses1,2. While this phenomenon was first described 
through the characterisation, and later development, of GPCR ligands capable of stabilising different receptor 
conformations to bias downstream signalling1,3, the mechanisms that drive physiological signalling bias are less 
well understood. Two key contributors to this signalling bias are changes in receptor sequences arising from 
genetic variation (e.g. receptor polymorphisms4,5), and the system-specific expression of GPCR signalling 
components6.  
  
An important source of functional diversity is the generation of protein isoforms by mechanisms such as tissue-
specific alternative splicing, and through the use of alternative transcription start and termination sites7,8 (Fig. 
1a; reference vs. non-reference isoforms). Some GPCRs are known to have multiple isoforms with distinct 
signalling properties9–12 and alternative splicing events are known to affect different receptor regions13. 
However, the extent to which receptor isoforms generate structural and functional diversity, their pattern of 
expression in different human tissues, and how combinatorial isoform expression can generate diverse 
signalling states, thus contributing to physiological signalling bias, is fundamentally unexplored. Considering 
over one-third of the drugs in the clinic target this receptor family14,15, understanding how isoform diversity can 
influence function is not only important to understand receptor physiology, but also to assess how this diversity 
may affect GPCR drug response.  
 
In this work, through a comprehensive data analysis approach, we have obtained a receptor-wide view of GPCR 
isoform diversity in humans. Our results show how non-olfactory human GPCRs of different classes can exhibit 
diversity in receptor structural segments involved in interaction with extracellular ligands and with intracellular 
signalling partners. They also provide an isoform expression map across human tissues, that reveals how tissue-
specific combinations of GPCR isoforms with distinct ligand binding and pharmacological properties could 
contribute to system-specific receptor signalling. The resulting characterisation of GPCR isoform diversity has 
been made accessible through the GPCRdb web-resource16 (currently available at 
https://gpcrdb.org/protein/isoforms). This can serve as a roadmap to assess the isoform diversity for any given 
receptor and understand how combinatorial receptor isoform expression can determine signalling response and 
contribute to physiological signalling bias.     
 
Structural changes in receptor isoforms diversify receptor function  
 
Isoform diversity exists across different GPCR classes  
To assess the prevalence of multiple receptor isoforms in all non-olfactory GPCRs, we combined transcript-
level mRNA expression data from the Genotype-Tissue Expression (GTEx) Consortium17,18, which includes 
gene expression information from 30 human tissues of ~700 donors, with sequence and structural annotations of 
receptors from the GPCRdb16 (Fig. 1b). We then filtered transcripts by expression level, by annotation as 
protein-coding in Ensembl19, and, where applicable, by the integrity of the signal peptides required for GPCR 
synthesis in the endoplasmic reticulum (ER), as annotated in UniProt20. In order to ensure that all isoforms in 
our study were transmembrane proteins, we created receptor-specific multiple sequence alignments of all the 
isoforms found for every GPCR. These alignments were then used to select only those receptor isoforms with 
one or more conserved transmembrane segments, as annotated in GPCRdb (Fig. 1b, Methods). In this manner, 
we identified 363 different receptors and 625 distinct GPCR isoforms in the GTEx dataset (that is, 363 reference 
isoforms corresponding to GPCRdb receptor sequences, and 262 non-reference isoforms). 136 receptors (38%) 
have two or more isoforms that are expressed in four or more GTEx donors (see Methods). Notably, this 
observed isoform diversity can be found in multiple GPCR classes and is not restricted to receptors that couple 
to particular G protein subtypes or that bind specific types of endogenous ligands (Extended data Fig. 1).  
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Receptor isoforms generate structural diversity 
Considering the prevalence of GPCRs with multiple isoforms across receptor classes, we assessed how isoforms 
contribute to variation in receptor structure. To this end, using our previously-created receptor-specific multiple 
sequence alignments (see Methods), we assessed which receptor structural segments – as annotated in 
GPCRdb21 – were more frequently altered in GPCRs with more than one isoform. To better characterise their 
structural changes, all non-reference isoforms preserving at least one transmembrane segment from the GPCRdb 
reference isoform (262 non-reference isoforms from 136 receptors) were classified in two groups: topologically 
preserved (Fig. 2a, dark blue) when they preserved all transmembrane (TM) segments found in the reference 
isoform; and topologically truncated (Fig. 2a, light blue), when one or more TM receptor segments were altered 
(See Extended data Fig. 2 for more details on this classification). 
 
To understand which structural segments are simultaneously altered in non-reference isoforms, we created 
structural fingerprints, which are a representation of the structural segments that are preserved or changed with 
respect to the reference isoform (Fig. 2a). Each of the 16 receptor segments forming the fingerprint is shown as 
a circle; with preserved segments shown in black and varying or missing segments shown in grey (Fig. 2a; A 
typical GPCR has 16 structural segments, which include the N- and C-terminal segments, the 7 transmembrane 
helices, helix 8 and the 3 intra- and 3 extra-cellular loops). Assessing all the detected structural fingerprints 
makes it possible to determine the prevalence of different structural changes across the GPCR isoforms, and 
how commonly they appear in topologically preserved (dark blue) and truncated (light blue) isoforms (Fig. 2b). 
Analysis of the resulting 55 distinct structural fingerprints reveals that after the reference isoform (containing all 
16 structural segments), the most frequent structural fingerprint represents changes in the receptor N-terminal 
segment. This structural fingerprint appears in 65 different receptor isoforms (from 47 receptors), which all 
preserve the receptor seven transmembrane helix (7TM) topology. The second most prevalent structural 
fingerprint corresponds to 32 non-reference isoforms (from 23 receptors) with alterations in the C-terminal 
segment, again preserving the 7TM topology. Following these, we find three structural fingerprints 
corresponding to truncated receptor isoforms and a structural fingerprint that includes receptors with an altered 
helix 8 and C-terminus (Fig. 2b).  
 
Interestingly, we find an enrichment in class B2 (adhesion) receptors for isoforms with N-terminal variation and 
in class C receptors for isoforms with C-terminal changes (Fig. 2b, inset). This could, perhaps, be related to the 
different functional relevance of these segments in these classes. For instance, as the large N-terminal region of 
class B2 adhesion receptors tends to interact with diverse matricellular and membrane-exposed proteins, 
receptor isoforms with variation in their N-terminus could possibly rewire interactions with extracellular 
proteins22. Similarly, as C-terminal segments can mediate oligomerisation in class C receptors, receptor 
isoforms with different C-terminal sequences are likely to show different oligomerisation patterns23. While 
these are likely functional effects of changes in the N- and C-terminal segments in receptors from these classes, 
the exact effect on signalling response will vary depending on the receptor and cellular context and needs to be 
validated experimentally (see next section). Together, these observations suggest that a large number of non-
reference receptor isoforms can generate structural diversity that could affect functional hotspots, while 
preserving the 7TM architecture. 
 
Structural diversity and functional impact 
The structural variability as captured by the structural fingerprints raises the question as to how many of the 
observed fingerprints correspond to functional isoforms. This is particularly pertinent for the highly truncated 
receptor isoforms (i.e. those missing many transmembrane segments), which are less likely to productively bind 
and couple to intracellular transducers. To link structural fingerprints with likely functional impact, we first 
determined which receptor isoforms have been previously identified and functionally characterised by 
performing an extensive literature search. We obtained evidence of functional changes in a number of non-
reference receptor isoforms belonging to 12 of the structural fingerprints (marked with asterisks in Fig. 2b). In 
this manner, we could link these structural fingerprints to different functional changes reported in the literature 
(Fig. 2c, Supplementary Table 1). 
 
This analysis highlighted that isoforms with an alternative N-terminus are the most frequently characterised 
(Fig. 2c) and that variation of this receptor region tends to alter either ligand binding and/or efficacy. For 
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instance, the cannabinoid receptor (CNR1), has two non-reference isoforms with decreased binding affinity for 
endocannabinoids, and for which both endogenous and synthetic ligands display altered potency24. Similarly, for 
the chemokine receptor CXCR3, two non-reference isoforms with different N-termini display unique efficacy 
profiles towards Gαi activation, β-arrestin recruitment, and ERK1/2 phosphorylation for the 
chemokines CXCL4, CXCL9, CXCL10, and CXCL125. For receptors with an altered C-terminus, the observed 
functional outcomes are more diverse, but are mostly related to changes in receptor coupling, internalisation and 
membrane trafficking. For example, in the thromboxane A2 receptor (TA2R), a non-reference C-terminal splice 
variant retains the capacity of the reference isoform to signal via phospholipase C, but inhibits cAMP 
production instead of stimulating it26. In this manner, TA2R isoforms rewire G protein coupling preferences. 
Given that post-translational modifications can drive multiple steps of the GPCR life cycle27, we also analysed 
whether experimentally validated C-terminal phosphorylation motifs were conserved in non-reference isoforms. 
We observed that, for a number of receptors, phosphorylation sites that were analysed by mass spectrometry and 
further characterised in functional studies, are not retained in the non-reference isoform (Extended data Fig. 3). 
Experimental perturbation of such functional sites in C-terminal regions has been shown to result in altered 
desensitization and recycling of the reference receptor isoforms (Extended data Fig. 3) and suggests possible 
differences in trafficking in the non-reference isoforms lacking these sites.  
 
In highly truncated isoforms, such as those missing all segments from the third or fourth transmembrane helix, 
the truncated receptor does not always reach the plasma membrane but can still have a dominant negative effect 
on the full-length reference isoform by sequestering it in the endoplasmic reticulum. This has been seen in 
isoforms of the serotonin 2C (5HT2C) and the gonadotropin-releasing hormone (GNRH) receptors28,29. In other 
cases, truncated receptors could modulate the function of other GPCRs. This seems to be the case for an isoform 
of the µ-opioid receptor (OPRM), which lacks both the N-terminus and helix 1. Knocking out this particular 
isoform in mice can lead to a loss of analgesic action for delta and kappa opioids, as well as those mediated by 
α2-adrenergic ligands30.  
 
We observed that many, as yet uncharacterised, receptor isoforms detected in our analysis (shown in grey in 
Fig. 2c), have the same structural fingerprints as receptor isoforms where literature evidence points to specific 
functional changes (shown in black in Fig. 2c). This topological similarity of uncharacterised isoforms to the 
annotated isoforms (i.e. sharing the same structural fingerprint) can suggest the potential functional impact of 
structural alterations in these unstudied receptor isoforms. This knowledge could help prioritising experiments 
to elucidate the functional consequences of structural variation in specific receptor isoforms. However, as we 
observe in Fig. 2c, the same fingerprint can be related to multiple outcomes for different receptor isoforms, 
stressing that functional inference through structural fingerprint similarity should only be used as a guide. The 
exact functional effect of a receptor isoform variation will need to be experimentally studied in a relevant 
cellular or physiological context to understand the real impact of structural changes on receptor signalling (see 
below). 
 
Combinatorial expression of isoforms can generate physiological signalling bias  
 
All tissues show combinatorial expression of isoforms  
Since many of the observed isoforms may impact the way in which extracellular cues are detected and 
transmitted into intracellular signals, we analysed whether the expression of the 625 previously detected 
receptor isoforms (reference and non-reference) was ubiquitous or confined to particular tissues (see Extended 
data Fig. 4a and Supplementary Table 2). Interestingly, comparing the median expression of all isoforms of a 
particular receptor in each of the GTEx tissues reveals that the reference isoform is not always the most highly 
expressed one (Extended data Fig. 4b). The number of receptors that are expressed in a given tissue differs 
widely: with pancreas expressing the lowest number of different receptors (149 GPCRs), and the pituitary 
expressing the highest number of receptors (236 GPCRs; Fig. 3a). However, the mean number of expressed 
isoforms per receptor in each tissue remains consistently over 1 ranging from 1.42 to 1.72 (conversely, if only 
one isoform was expressed for each receptor in a tissue, the mean number of expressed isoforms would be 1). 
Our results mean that, in every tissue, one or more receptors express multiple isoforms simultaneously (i.e. we 
always observe combinatorial expression). This is also the case if we analyse the data for each donor 
independently (Extended data Fig. 4c), with the mean number of isoforms per receptor in different tissues 
ranging from 1.05 to 2.04. This points to the existence of GPCRs with multiple isoforms in all of the 30 
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analysed tissues. In other words, reference and non-reference isoforms are extensively co-expressed in all these 
tissues.  
 
Receptor isoform combinations can influence signalling response 
Taking this into account, we then investigated whether all isoforms of a receptor are present in all tissues where 
a receptor is expressed, or whether distinct combinations of receptor isoforms can exist in different tissues (see 
Extended data Fig. 4d). To address this, we computed the number of unique combinations of receptor isoforms 
that are co-expressed in all GTEx tissues (referred to as the number of tissue expression signatures; Fig. 3b). If 
receptor isoforms have different signalling properties, different isoform combinations in human tissues could 
result in unique signalling outcomes in response to the same input signal. Thus, representing the number of 
tissue expression signatures of a receptor (Fig. 3b, right) can provide insights into how tissue-specific isoform 
expression can contribute to complex responses upon systemic receptor activation. As an example, both the 
cannabinoid receptor 1 (CNR1) and the Adhesion G protein-coupled receptor E2 (CD97) have three different 
isoforms. However, we find four different tissue expression signatures for CNR1 but only one for CD97. In 
other words, we find that the three CNR1 isoforms can be expressed in four different combinations across 
tissues, while only one combination exists for CD97, in which all isoforms are consistently expressed in all 
tissues. This indicates that the CNR1 may present more diversity in signalling responses depending on what 
combination of isoforms are expressed in the different tissues compared to CD97. These observations 
collectively suggest that it may not be enough to characterize individual receptor isoforms independently or to 
analyse how many isoforms a receptor has but highlights the need to identify how many distinct isoform 
combinations exist, and how they can collectively influence receptor signalling responses in different tissues.  
 
Receptor isoform combinations diversify signalling outcomes and result in signalling bias 
In order to explore this further, we focused on CNR1 and the gastric inhibitory polypeptide receptor (GIPR) as 
two case studies. As mentioned above, the CNR1 receptor has two non-reference isoforms that are topologically 
preserved. They vary in their N-terminal segments with respect to the reference isoform and this results in 
altered ligand binding and potency when compared to the reference isoform (see Extended data Fig. 5a and 
Supplementary Table 1). If we consider the tissue distribution of these two topologically preserved non-
reference isoforms together with that of the reference isoform, we observe that different tissues express different 
isoform combinations (Fig. 3c). Several of these tissues are known to be physiologically relevant for 
cannabinoid action such as brain, stomach, pituitary or adipose tissue. To assess whether distinct isoform 
combinations could result in system-specific signalling, we characterised the contribution of reference and non-
reference isoform combinations to CNR1 pharmacology in HEK-293 cells.  
 
Because the primary effect of CNR1 is to inhibit adenylate cyclase through Gαi (Fig. 3d), we measured cAMP 
levels using a FRET sensor in live cells31. The initial FRET ratios were comparable in cells expressing and not 
expressing a FLAG-tagged reference CNR1 isoform (Extended data Fig. 5b, inset). In cells expressing CNR1, 
forskolin-stimulated cAMP levels were lower than in cells not expressing the receptor (Extended data Fig. 5b). 
The lower cAMP levels are consistent with a high basal activity of this receptor, which is likely related to the 
production of endogenous cannabinoids in line with previous studies32–34. This trend was reversed by both 
Rimonabant, a CNR1 inverse agonist that was withdrawn from the clinic by the European Medicines Agency as 
an anti-obesity drug due to life threatening psychiatric side effects35 and the neutral antagonist AM4113 
(Extended data Fig. 5c-g). We then tested whether co-expression of the non-reference isoforms 1 and 2, at 
equivalent relative expression levels (Extended data Fig. 5h), influenced forskolin-stimulated cAMP levels in 
cells already expressing the reference isoform. Co-expression of a SNAP-tagged isoform 1, but not an 
equivalent level of a SNAP-tagged reference isoform, together with a FLAG-tagged reference isoform, led to a 
significant decrease in endpoint cAMP (Fig. 3d and e). In contrast, co-expression of isoform 2 caused a faster 
forskolin response and higher total cAMP levels (Fig. 3d and f). These observations suggest that both the extent 
and rate of CNR1 signalling could be modulated by co-expression of different CNR1 isoforms. Notably, in cells 
expressing the reference isoform along with non-reference isoform 2, Rimonabant caused higher cAMP levels 
in a larger fraction of cells, when compared to cells expressing only the reference isoform (Fig. 3g).  
 
In the case of GIPR, we detected one non-reference isoform with a different C-terminus (Extended data Fig. 
5i). An analysis of the tissue distribution of GIPR (Fig. 3h) revealed that adipose tissue, adrenal gland, pancreas 
or brain, where this receptor has regulatory functions, express either the reference isoform alone or both 
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isoforms in combination. We did not observe any tissue that only expressed the non-reference isoform. Given 
that the C-terminal region is important for coupling to G proteins and recruitment of β-arrestin, we measured the 
pharmacological response of the receptor to the gastric inhibitory polypeptide (GIP) by considering 4 different 
experimental measurements (production of cAMP, mobilisation of intracellular calcium (Ca2+)i, and recruitment 
of β-arrestin 1 and 2) in HEK-293T cells. Interestingly, although receptor signalling is consistently reduced in 
the presence of the non-reference isoform alone (see Extended data Fig. 5j-k), co-expression of both isoforms 
has a different effect on the engagement of different signalling transducers as inferred through the second 
messenger measurements (Fig. 3i). Specifically, we measured and compared the response to GIP in cells 
expressing only the reference isoform and cells co-expressing the reference and non-reference GIPR isoforms. 
We observed that the efficacy (Emax) of GIP is most affected while measuring (Ca2+)i release, while its potency 
(pEC50) is most affected while measuring cAMP signalling. These differences in downstream signalling 
response, mediated by different G protein subtypes, suggest that the expression of only one or both receptor 
isoforms can result in physiological signalling bias in different systems, in the presence of the same GIP 
concentrations. 
 
Taken together, our observations suggest that, for receptors with multiple isoforms, distinct isoform 
combinations can diversify signalling outcomes in response to the same ligand. In other words, systems 
expressing different isoform combinations can vary in the overall pharmacological response to the same ligand.  
These observations also highlight the need to characterise which receptor isoforms are expressed in a system of 
interest, so that any model used for characterising receptor pharmacology or for assay development (e.g. for 
drug compound screening) will allow measurements to reflect the combined signalling effects of receptor 
isoforms. This can be important for two reasons: on the one hand, if the experimental system does not mimic the 
one we intend to understand (e.g. because we only overexpress a single receptor isoform), it may not provide a 
translatable readout; on the other hand, ignoring the isoforms already expressed in that experimental system 
could contribute to biased measurements with respect to the biological system that is being characterised. 
Collectively, the observations on CNR1 and GIPR show how the expression of distinct combinations of GPCR 
isoforms in different tissues has the potential to generate system-specific signalling states, which, in turn, can 
impact ligand and drug response and can contribute to physiological signalling bias.  
 
Receptor isoforms in GPCR drug targets  
 
Tissue expression signatures of GPCR drug targets 
Since more than one-third of all approved drugs target a GPCR14,15, we analysed how many of these drug targets 
had multiple isoforms and how complex their tissue expression signatures were. To this end, we analysed 111 
GPCRs that have been described as targets of 474 FDA approved drugs36 (Fig. 4a). We found that 42% of the 
known GPCR drug targets have more than one isoform. Interestingly, we found extensive variation in the 
number of approved drugs for receptors with the same number of tissue expression signatures (Extended data 
Fig. 6). This highlights that the currently approved drugs target GPCRs with multiple isoforms that are 
expressed in different combinations in different tissues. The drug target with the highest number of tissue 
expression signatures, the adenosine 2A receptor (AA2AR with 13 unique combinations of isoform expression), 
exemplifies the possible impact that isoform diversity could have in tissue-specific drug response. These tissue 
expression signatures include different combinations of a series of highly truncated isoforms, as well as a 
topologically preserved non-reference isoform. The latter has a shorter C-terminus lacking a phosphorylation 
site that, in the reference isoform, is crucial for heterodimerisation of AA2AR with the dopaminergic D2 
receptor37 (see Extended data Fig. 3). Formation of this dimer, which results in negative allosteric modulation 
of ligand binding in the partner receptor38, is believed to be related to the antiparkinsonian effects of AA2AR 
antagonists39. Taken together, these observations suggest that changes in distribution of particular receptor 
isoforms could not only result in a tissue-specific response to systemically administered drugs, but also may 
affect the efficacy of drugs targeting other interacting GPCRs.  
 
Non-reference receptor isoforms as potential drug targets 
Although the observed structural diversity and tissue-specific distribution of isoforms may confound our 
understanding of the systemic effects of drugs targeting some GPCRs, it can also present an opportunity to 
specifically target particular receptor isoforms with desired tissue expression patterns. To assess whether clinical 
phenotypes can be uniquely associated with the non-reference isoforms, we analysed the recently generated data 
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from the UK Biobank and available through Gene ATLAS40. Gene ATLAS presents associations between 
polymorphisms (assessed through genotyping specific single nucleotide polymorphisms, SNPs) and phenotypes 
from ~500,000 individuals in the UK population. Analysis of the statistically significant associations in this 
dataset revealed the existence of SNPs within the non-reference isoforms that were uniquely associated with 
disease-related phenotypes (see Extended data Fig. 7 for examples and Supplementary Table 3). This genetic 
evidence of isoform-specific phenotypes implies that (a) whole genome sequencing might allow discovery of 
new associations between non-reference isoform variants and clinical phenotypes and (b) phenome-wide 
association studies accounting for multiple receptor isoforms may reveal previously underappreciated isoform-
specific therapeutic indications. 
 
Achieving isoform-level selectivity for new drug candidates will likely require isoform-specific structural 
features to be ligand-accessible (Fig. 4b). Such unique isoform structural regions should ideally correspond to 
one or more extracellular receptor segments with the capacity to affect ligand binding affinity or kinetics. By 
filtering our dataset using this criterion, we obtained 75 topologically preserved non-reference receptor isoforms 
with potentially different ligand binding interfaces. In terms of their tissue expression, and to allow for isoform 
selectivity, non-reference isoforms should display a different tissue distribution as compared to the reference 
isoform or show a more constrained tissue expression with the potential to avoid on-target side effects in tissues 
unrelated to the drug treatment. By further applying these criteria, we obtained 62 isoforms from 40 different 
receptors that could be further assessed for pharmacological interest (Supplementary Table 4).  
 
To highlight the challenges and opportunities that drugging such isoforms could present, we chose one of the 
isoforms detected for further characterisation. GPR35, still considered an orphan receptor, is currently the target 
of the approved mast cell stabilizer lodoxamide, which is administered topically for the treatment of allergic 
keratoconjunctivitis41. It has also been described as the target of pamoic acid, a partial agonist that has been used 
as an excipient in different drug formulations (from antihelminthic to antipsychotic drugs), and has been found 
to attenuate visceral pain in mice42. Therefore, GPR35 agonists could be of therapeutic interest not only in 
allergy, but also in neuropathic pain. In addition to the reference isoform, we detected a non-reference isoform 
that contains an additional 31 amino acids at its N-terminus (Fig. 4c; top and Extended Fig. 6b). The reference 
isoform is more ubiquitously expressed, whereas the non-reference isoform is expressed only in some tissues. 
The two isoforms have different patterns of expression in tissues of potential interest such as in lungs, where 
only the reference isoform is expressed, or in nerve, where both isoforms are co-expressed. Pharmacological 
characterisation of the efficacy of different agonists for these isoforms in HEK-293T cells (Fig. 4c) reveals that 
the non-reference isoform does not change Gα13 or β-arrestin 2 signalling when compared to the reference 
isoform. However, for each agonist tested, the maximal signal intensity generated was markedly lower (Fig. 4c), 
while potency remained comparable (Extended Fig. 6c)  
 
This observation points to the possibilities and challenges that some of the detected N-terminal receptor 
isoforms may present: when designing receptor agonists, exploiting the structural differences found between 
isoforms could allow activating the less ubiquitously expressed GPCR isoforms in a tissue of interest, while 
sparing receptor activation in others where the more ubiquitously expressed isoform of the receptor will be 
present. This would require drug screening to be conducted considering non-reference isoforms, rather than 
focussing on reference isoforms only, which is currently largely the case. For GPR35, this could lead to the 
detection of new drug candidates specifically targeting the extended N-terminus of the non-reference isoform. 
These compounds could still act as agonists in tissues such as nerve to treat visceral pain, while leaving many 
other tissues (where only the reference isoform is expressed) unaffected. On the contrary, when trying to block 
receptor signalling, all receptor isoforms expressed in a tissue of interest should be considered, to avoid the risk 
of not fully inhibiting GPCR signalling or, at least, of encountering unexpected pharmacodynamics issues. 
Beyond the receptor isoforms with changes in ligand accessible regions, developments in the design of new 
allosteric modulators, intra-cellular compounds that influence receptor signalling43 and RNA based approaches44 
that can selectively silence the expression of specific receptor isoforms might expand the collection of receptor 






Further evidence for GPCR isoforms and considerations 
 
While our study reveals extensive structural and combinatorial diversity arising from receptor isoforms, an 
important next step is a proteome-wide characterisation to gain insights into relevant receptor isoforms in 
different tissues. Full coverage of membrane proteins such as GPCRs by techniques such as mass spectrometry 
(MS)-based shot-gun proteomics is still challenging, due to their low abundance and their membrane spanning 
nature45. Furthermore, characterization of isoforms is even more difficult, as protein segments that discriminate 
isoforms represent a small fraction of detectable peptide fragments of a receptor in MS experiments. Despite 
these challenges, an analysis of multiple proteomics datasets revealed the existence of peptides that can uniquely 
discriminate both reference and non-reference isoforms from the GTEx dataset (see all the available isoform-
specific MS evidence from ProteomicsDB in https://gpcrdb.org/protein/isoforms (Extended data Fig. 8), and 
further analyses in Extended data Fig. 9 and Supplementary Table 5). As the changes in the relative 
expression levels of receptor isoforms across tissues could be a source of system bias46, another direction for 
further characterisation of receptor isoforms is to accurately quantify their abundance in specific systems. This 
would not only ensure characterisation of the receptor isoforms at the protein level, but also allow the detection 
of some lowly expressed but functionally relevant isoforms that may have not been accounted for in our 
analysis. In this context, further efforts for protein quantification in the GTEx project47, together with technical 
developments in focused proteomics approaches48, should allow for a deeper characterisation and quantification 
of receptor isoforms in the near future.  
 
The GTEx data analysed here currently provides tissue-level spatial resolution of isoform expression. This 
implies that some of the isoforms we find in a tissue may be confined to particular cell types. It also means that, 
whenever possible, the multiple isoforms detected for the different receptors should be further characterised at 
the cell type level, and ideally in individual cells. To address this, we first investigated whether homogeneous 
cell populations still express multiple isoforms per receptor by characterising 11 widely-used human cell lines. 
Consistent with our tissue-level analysis, we find receptors with multiple isoforms in all cell lines (Extended 
data Fig. 10a-c, Supplementary Table 6). The observed isoform diversity in cell lines has important 
implications for the pharmacological characterisation of new ligands in these commonly used systems. Because 
the collection of isoforms that is expressed in each cell line may vary, this might greatly impact receptor 
pharmacological readouts. Immortalised cell lines, however, are characterised by genomic and expression 
heterogeneity, and may not mimic physiological expression patterns of GPCR isoforms. For this reason, we also 
analysed whether receptor isoforms are co-expressed in primary cells from human tissues. An analysis of GPCR 
expression in healthy human pancreatic cells, obtained by SmartSeq single cell RNA sequencing49, revealed the 
presence of multiple isoforms per receptor in each of the analysed cell types (α, β, δ, acinar, ductal and 
mesenchymal pancreatic cells) confirming the prevalence of isoform combinatorial expression at the single cell 
level beyond cancer cell lines (Extended data Fig. 10a-c, Supplementary Table 6). On-going international 
projects such as the Human Cell Atlas (https://www.humancellatlas.org/), combined with ad-hoc investigations 
on the detection of protein isoforms described in our study, will allow a more comprehensive investigation in 
the future into the precise pattern of receptor isoform co-expression in individual cells and cell types from 
different tissues. 
 
In tissues such as the nervous system, it has been shown that different isoforms could be expressed in different 
parts of the same cell. For example, the long form of the D2 dopamine receptor is classically post-synaptic, 
while the short form is pre-synaptic50. While current large-scale datasets and high-throughput experimental 
approaches cannot reveal such patterns of expression, we hope that our analysis, and the resource of human 
receptor isoforms that we present here, will allow individual labs interested in a specific receptor and its 




From a canonical to a context-specific view of GPCR signalling 
Our integrative analysis (Fig. 5) highlights how some GPCR genes can give rise to a collection of receptor 
isoforms with unique structural and signalling properties, and how the combinatorial expression of these 
isoforms might diversify receptor signalling response in different human tissues. These findings imply that, for 
receptors with more than one isoform, the observed signalling readout upon receptor activation by a particular 
	 9 
ligand may be a composite effect of that ligand acting on a collection of receptor isoforms present in the system 
(Fig. 5). Furthermore, given that isoform composition can differ between tissues, activation by the same ligand 
could result in a variety of system-specific downstream signalling responses (Fig. 5). Thus, when interpreting 
the action of natural or synthetic ligands for receptors with multiple isoforms, we may need to move from the 
canonical view to a context-specific view of GPCR signalling, where one considers how the structural diversity 
and combinatorial isoform expression collectively drive system-specific signalling response (where a system 
can consist of individual cells, tissues or an entire organism, Fig. 5).  
 
This means that, to extrapolate ligand effects in particular tissues, the choice of a model system may need to 
closely mimic the composition of receptor isoforms in the key sites of action. In other words, our observations 
point to the need of a critical assessment of isoform composition in cells, tissues and in other model organisms, 
as a key consideration that must be incorporated to successfully translate readouts from cell, tissue and animal 
models to studies on human physiological responses and clinical trials. The existence of non-reference isoforms 
and their association with specific clinical phenotypes in the human population points to new opportunities to 
understand human physiology and for drug development. Specifically, non-reference isoforms with unique 
tissue expression patterns and variation in specific structural segments might represent new drug targets. Future 
research accounting for context-specific GPCR signalling and exploiting isoform selectivity might therefore 
open the door for the development of drugs (e.g. small molecules and RNA based approaches) addressing new 
and unmet clinical needs, as well as potentially minimizing on-target side effects. We hope that, beyond the 
proof-of-principle characterisation presented here, our work will inspire more detailed research programmes in 
academia and industry focussed on particular GPCRs. To facilitate this, we have developed a resource that 
allows exploring GPCR isoform diversity in humans and assessing the potential for isoform-dependent 
signalling responses in any given receptor (Extended data Fig. 8 and https://gpcrdb.org/protein/isoforms).  
 
Conclusion 
In biology, it has been generally appreciated that gene duplication and generation of isoforms tend to be 
inversely correlated mechanisms that provide new material for diversifying biological functions51. Our 
observation about the prevalence of GPCR isoforms in humans suggests that gene duplication and isoform 
diversity in this family have been simultaneously exploited during evolution. The finding that functionally 
diverse isoforms can be uniquely co-expressed in different tissues points to a strategy by which organisms can 
finely calibrate the way in which individual tissues respond to the same extracellular stimulus. Unlike 
differential transcription of gene duplicates, the fact that isoforms can be post-transcriptionally regulated might 
represent a rapid mechanism to diversify cell response to the same ligand. In this manner, generation of isoform 
diversity in different tissues could have been exploited by multi-cellular organisms to rapidly mount different 






Transcriptomics, protein sequence and pharmacological data collection. In order to collect information for 
all human GPCRs, we obtained GPCRdb names, Uniprot identifiers and receptor class annotations of all GPCRs 
in the GPCRdb16 database via the REST API and with help of the jsonlite R package. We then used those 
Uniprot identifiers to obtain associated information from Ensembl19 (GRCh37 assembly) using the R BioMart 
interface52. Specifically, we collected HUGO Gene Nomenclature Committee (HGNC) symbols, gene and 
transcript IDs, transcript biotype and signal peptide annotations and protein sequences for all GPCR transcripts 
in Ensembl. Only transcripts belonging to the ‘protein coding’ biotype (i.e. excluding short and long non-coding 
and nonsense-mediated decay transcripts, pseudogenes, etc.) and with a preserved signal peptide (for those 
receptors with one annotated) were kept for further analysis. Using the Ensembl transcript IDs, we then used 
transcript-level Transcripts Per Kilobase Million (TPM) data (GTEx_Analysis_2016-01-
15_v7_RSEMv1.2.22_transcript_tpm.txt) from the GTEx18 Portal  to filter for GPCR transcripts detected by 
TruSeq.v1 technology (as annotated in the database in GTEx_v7_Annotations_SampleAttributesDS.txt) and 
expressed at ≥1 TPM in at least 4 different GTEx donors (using donor annotations found in 
GTEx_v7_Annotations_SubjectPhenotypesDS.txt). Please refer to the original GTEx publications for further 
information on RNAseq quality control and analysis18,53. The expression cut-off was chosen both to match the 
cut-off used in another publication from the GTEx consortium that focussed on the analysis of splice variants54, 
and to ensure that any non-reference isoform studied would have a high likelihood to be translated into protein 
and have an effect when combinatorially co-expressed with the reference isoform. In parallel, the donor cut-off 
was chosen after analysing which was the lowest number of donors that would still capture all known reference 
receptor isoforms (in our case, 4 donors for the reference ADGRB2 receptor). Furthermore, in order to analyse 
whether the number of isoforms per receptor was associated with any receptor pharmacological features, we 
used the jsonlite R package to query the REST API from the Guide to Pharmacology55 database. This allowed 
the GPCR HGNC symbols to be linked to annotations on receptor natural/endogenous ligands and transduction 
mechanisms.  
 
Structural fingerprints and functional annotation. For receptors with more than one isoform, we analysed 
the structural segments that differed between reference and non-reference isoforms. To do so, we used the 
protein sequences from Ensembl to obtain a sequence alignment using MUSCLE56 with default parameters (gap 
extension set at -1.0). In the case of receptors with transcripts coding for the same amino acid sequence (i.e. 
with just the 5’ or 3’ UTRs being different), we retained one representative sequence only. We also used 
GPCRdb receptor names to download information on receptor segments associated with every receptor residue 
from GPCRdb as detailed in the previous section. For each multiple sequence alignment, we found the Ensembl 
transcript corresponding to the structurally annotated sequence in GPCRdb and considered it our reference 
receptor sequence; receptors for which none of the isoforms could be assigned to a GPCRdb reference (FFAR4, 
GPR111, GPR107, GPRC5C, LPHN3, LRB4R2 and OR51E1) were excluded from further analysis. For non-
reference receptor isoforms, we used the multiple sequence alignment to determine which GPCRdb annotated 
receptor segments were the same as in the reference and which were different or absent to obtain a “structural 
fingerprint”. Each fingerprint contains information about the 16 structural segments that constitute a GPCR, and 
whether they are conserved with those in the GPCRdb annotated reference or they differ (i.e. have a different 
sequence or are missing). In this manner, we generated a 16-dimensional vector with 1s and 0s, denoting 
conserved or altered segments, for each isoform. In the graphical representation of these fingerprints (see Fig. 
2), conserved segments are shown as dark circles, and varying or missing segments as grey circles. To ensure 
that our analysis was centred on isoforms that were anchored to the membrane we excluded non-reference 
isoforms that did not have at least one transmembrane structural segment in common with their reference 
isoform. The resulting non-reference isoforms were classified as ‘topologically preserved’ when all receptor 
transmembrane segments of the reference isoform were preserved and ‘topologically truncated’ when at least 
one annotated transmembrane segment was altered (missing or differing) in comparison to the reference 
isoform. To assess the functional importance of the non-reference isoforms detected in GTEx, we performed a 
comprehensive literature search for each receptor with multiple isoforms in the PubMed database and collected 
all references in which a human non-reference isoform matching one of our analysed transcripts had been 




Characterisation of tissue expression and tissue expression signatures. Using tissue annotations for the 
transcript-level TPM data from the GTEx Portal (GTEx_v7_Annotations_SampleAttributesDS.txt), we first 
calculated the number of receptors and the mean number of isoforms per receptor in all 30 tissues analysed in 
the GTEx project, considering expression data from all available donors. We also calculated the mean number 
of isoforms per receptor and tissue on a donor-by-donor basis. The tissues include: Brain, Nerve, Pituitary, 
Adrenal Gland, Thyroid, Blood Vessel, Blood, Spleen, Heart, Muscle, Bladder, Kidney, Salivary Gland, 
Esophagus, Stomach, Small Intestine, Liver, Pancreas, Colon, Adipose Tissue, Skin, Lung, Breast, Ovary, 
Fallopian Tube, Uterus, Vagina, Cervix Uteri, Prostate, and Testis. In the case of transcripts that code for the 
same isoform (i.e. synonymous transcripts: same protein sequence but different 5’ or 3’ UTRs), we considered 
the protein isoform to be expressed in all tissues where the synonymous transcripts had been detected. To 
calculate the most prevalent isoform per receptor in each tissue, we selected the isoform with the highest median 
expression considering all GTEx donor samples from that tissue. For the 136 receptors with more than 1 
isoform, we also obtained receptor-centric Nx30 binary matrices representing the presence or absence of 
receptor isoforms in different tissues considering all donors, where N is the number of unique isoforms of a 
particular receptor and 30 is the number of tissues analysed in GTEx. These matrices were then used to calculate 
the number of unique tissue expression signatures per receptor, that is, the number of unique combinations of 
receptor isoforms that are found across the different human tissues. 
 
CNR1 cloning and pharmacological characterisation. cDNA sequences for human CNR1 isoforms 1 and 2 
were used to generate gene blocks (Integrated DNA Technologies) which were cloned into a pcDNA3.1 
backbone with a SNAP tag using BamHI and XbaI sites. The human CNR1 reference isoform was cloned into a 
pcDNA3.1 backbone with an Influenza hemagglutinin signal sequence and a FLAG tag or SNAP tag using AgeI 
and XbaI sites. A mixed population of stable HEK-293 cells expressing the FLAG-tagged CNR1 reference 
isoform was generated using Geneticin selection. Cells were cultured in DMEM/High glucose supplemented 
with 10% Fetal Bovine Serum (FBS) and maintained at 37°C and 5% CO2. The FLAG-tagged CNR1 cell line 
was transfected with 300ng SNAP-tagged CNR1 reference isoform as a control or SNAP-tagged CNR1 non-
reference isoform 1 or 2 and 300ng cAMP fluorescence resonance energy transfer (FRET) sensor ICUE3, a gift 
from Jin Zhang (Addgene plasmid #6162231) using Effectene according to manufacturer’s standards and 
incubated for 5hrs at 37°C. Cells were imaged 48-72hrs after transfection. Prior to FRET experiments, cells 
were pre-treated with 500 µM phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) for 2hrs. Before 
imaging, cells were labelled with Alexa-568-conjugated M1 antibody (Millipore Sigma F3040) and 500nM 
SNAP-surface Alexa-Fluor 647 (New England BioLabs S9136S), for 10min at 37°C to label FLAG and SNAP 
tagged receptors, respectively. Cells were imaged in L-15 media supplemented with 1% FBS and 500 µM 
IBMX at 37°C in a temperature-controlled imaging chamber (In Vivo Scientific). Cells were imaged on a TiE 
inverted microscope (Nikon) with a 60x NA 1.49 Apo-TIRF objective (Nikon) with an iXon-888 Life EMCCD 
camera (Andor). Cells were selected for imaging based on expression of both a FLAG tagged and SNAP tagged 
isoform as well as the FRET sensor. Initial confocal slice images were acquired to record receptor expression. 
Relative expression of FLAG and SNAP isoforms was quantified using ImageJ. Briefly, the SNAP channel was 
used to generate a mask defining the membrane receptor region of the cell. This mask was applied to both the 
FLAG and SNAP channels and the mean fluorescence intensity of these regions was measured and expressed as 
a ratio, normalized to the mean ratio of the control ref+ref condition on a given day to account for variability in 
labelling and dye/antibody aliquots between experiments. Cells were imaged in widefield imaging mode for 
CFP (405 nm excitation, 400 emission filter), YFP or FRET (405nm excitation, 514 emission filter) and for the 
SNAP tagged isoform (647 nm excitation, 700 emission filter) every 30 sec with 5 frames of baseline before 5 
µM Forskolin (Fsk) addition to stimulate adenylyl cyclase activity. For experiments in which cells were pre-
treated with Rimonabant or AM4113, cells were pre-treated with antagonist for 5 minutes, and imaged over this 
time period, before the addition of Forskolin. In experiments addressing the effect of isoform expression on 
Rimonabant responses, cells were similarly imaged every 30 sec with 5 frames of baseline before 500nM Fsk 
addition, followed by 10 µM Rimonabant addition after 5 min. Images were exported in 16-bit tiff files and 
analysed using ImageJ to calculate the change in CFP/FRET ratio in each cell, as previously described57. All 
data were analysed using GraphPad Prism 7. All data points representing individual cells were normalized to the 
mean of the control condition for each day, to account for experimental variability between days. All data were 
analysed by one-way ANOVA (alpha=0.05), with pairwise comparisons made using either Sidak’s or Dunnett’s 
multiple comparisons. ANOVA p-values and those of associated post-hoc tests are provided in the figure 
legends. The asterisks denote p-value, * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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GIPR cloning and pharmacological characterisation. PCR amplicons of GIPR reference or GIPR isoform 1 
were ligated into either a pcDNA3.1(+)-sigNluc backbone (signal peptide from the murine 5-HT3R), or a 
pcDNA3.1(-)-Nluc backbone to generate Nluc-GIPR or GIPR-Nluc constructs, respectively. All cloning results 
were confirmed by Sanger sequencing (University of Cambridge). FLAG-GIPR reference was supplied by 
Sulieman Al-Sabah (University of Kuwait). β-arrestin1/2-YFP and GRK5 were supplied by Kathleen Caron 
(University of North Carolina at Chapel Hill). HEK-293T cells (ATCC58) were cultured in DMEM/F12 (Gibco), 
supplemented with 10% heat-inactivated FBS (Sigma) and 1% antibiotic antimycotic solution (Sigma) and 
maintained at 37 °C with 5% CO2 in a humidified environment. Transfections were performed using either 
Fugene HD (Promega) at a 1:3 w:v ratio of DNA:Fugene HD, in accordance with the manufacturer’s 
instructions, or polyethylenimine (PEI, Polysciences Inc.) and 150 mM NaCl at a 1:6 w:v ratio of DNA:PEI. 
HEK-293T cells were transfected with pcDNA3.1(-), FLAG-GIPR reference + pcDNA3.1(+)-sigNluc, Nluc-
GIPR isoform 1 + pcDNA3.1(-) or FLAG-GIPR reference + Nluc-GIPR isoform 1 at a 1:1 ratio. After 48 hours, 
350000 cells were washed three times in fluorescence activated cell sorting (FACS) buffer (PBS supplemented 
with 1% BSA and 0.03% sodium azide) before and after incubation with the appropriate antibody for 1 hr at 
room temperature in the dark; rat allophycocyanin (APC)-conjugated anti-FLAG monoclonal antibody, diluted 
1:100 (BioLegend); rabbit anti-Nluc polyclonal antibody, diluted 1:100 (Promega); or goat APC-conjugated 
anti-rabbit IgG polyclonal antibody 31984, diluted 1:150 (Thermofisher). APC intensity was measured using a 
BD Accuri C6 flow cytometer (BD Biosciences) Ex. λ 633 nm and Em. λ 660 nm. Data were normalized to the 
mean APC intensity of cells transfected with FLAG-GIPR reference + pcDNA3.1(+)-sigNluc (where expression 
of FLAG-GIPR reference was assessed) or Nluc-GIPR isoform 1 + pcDNA3.1(-) (where expression of Nluc-
GIPR isoform 1 was assessed) as 100% and pcDNA3.1(-) as 0%. For cAMP accumulation and (Ca2+)i 
mobilisation assays, HEK-293T cells were transiently transfected for 48h with GIPR-Nluc reference + 
pcDNA3.1(-), GIPR-Nluc isoform 1 + pcDNA3.1(-) or GIPR-Nluc reference + GIPR-Nluc isoform 1, at a 1:1 
ratio. GIP (GIP (1-42))-mediated cAMP accumulation was measured after 30 minutes stimulation, in the 
presence of 500 µM IBMX, using the LANCE® cAMP detection kit (Perkin Elmer) and a Berthold Mithras LB 
940 multimode microplate reader, as previously described59,60. Forskolin (100 µM) was used as a positive 
control. (Ca2+)i mobilisation was measured as previously described59. GIP (1-42) was robotically added using a 
BD Pathway 855 high-content bio-imager and images captured every ~0.5 seconds for 80 seconds. The image 
series were processed using Fiji (Is Just) Image J to correct for background fluorescence of the region of interest 
and determine the maximum intensity to generate concentration-response curves. Ionomycin (10 mM) was used 
as a positive control. To measure β-arrestin1/2 recruitment, HEK 293T cells were transiently transfected with β-
arrestin1/2-YFP, GRK5 and either GIPR-Nluc reference + pcDNA3.1(+)-sigNluc, GIPR-Nluc isoform 1 + 
pcDNA3.1(+)-sigNluc, GIPR-Nluc reference + Nluc-GIPR isoform 1 or GIPR-Nluc isoform 1 + Nluc-GIPR 
reference at a 5:4:1:1 ratio and grown overnight. 50000 cells per well were seeded into poly-L-lysine coated 
white 96-well plates (Perkin Elmer) in reduced serum media (MEM + 2% FBS + 1% antibiotic antimycotic 
solution). The following day, cells were incubated with coelenterazine h (5mM, diluted in PBS containing 0.49 
mM MgCl2.6H2O, 0.9 mM CaCl2.2H2O and 0.1% BSA) for 10 minutes. The bioluminescence resonance energy 
transfer (BRET) ratio (530 nm/460 nm) was measured every minute for 60 minutes after GIP (1-42) addition, 
using a Berthold Mithras LB 940 multimode microplate reader and data were corrected to vehicle treated 
samples. The peak GIP-induced ΔBRET ratio (530 nm/460 nm) for β-arrestin1 and β-arrestin2 recruitment (9 
minutes and 8 minutes, respectively) was measured using a Berthold Mithras LB 940 multimode microplate 
reader and data were corrected to vehicle treated samples. All data were analysed using GraphPad Prism 8.4. 
For cAMP accumulation, (Ca2+)i mobilisation and β-arrestin1/2 recruitment assays, data were fitted to obtain 
concentration-response curves using the three-parameter logistic equation (for pEC50 and Emax values) and were 
normalized to the GIPR reference response. To construct the radar plots, Emax or pEC50 values for each condition 
were subtracted from the GIPR-Nluc reference to produce ΔEmax or ΔpEC50 values. For cell surface expression 
assays, data were normalized to the APC intensity of cells transfected with FLAG-GIPR reference + 
pcDNA3.1(+)-sigNluc (where expression of FLAG-GIPR reference was assessed) or Nluc-GIPR isoform 1 + 
pcDNA3.1(-) (where expression of Nluc-GIPR isoform 1 was assessed) as 100% and pcDNA3.1(-) as 0%. 
Significance was determined using a Mann-Whitney test.  
  
GPR35 cloning and pharmacological characterisation. The GPR35 reference - Gα13 sensor is described fully 
in Mackenzie et al61 and an equivalent GPR35 isoform 1-Gα13 sensor was generated by replacement of GPR35 
reference with GPR35 isoform 1, which contains an additional 31 amino acids at the N-terminus but is 
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otherwise identical in sequence to the reference. These two constructs were transfected transiently into HEK-
293T cells using polyethylenimine linear MW-25000 2 days prior to experiments. Thirty minutes before the 
assay, cells were washed with Hanks Buffered Saline Solution containing 10 mM HEPES and incubated in the 
same buffer at 37°C. Because BRET provides a ratiometric signal and each sensor is a single polypeptide, 
outcomes are anticipated to be independent of expression levels, but this was assessed directly by recording 
levels of substrate-induced luciferase activity. HEK-293T cells were transfected transiently to co-express either 
GPR35 reference-eYFP or GPR35 isoform 1-eYFP and β-arrestin 2 tagged with Nanoluciferase61–63. Agonist-
induced proximity between the eYFP and nanoluciferase generated BRET upon addition of the luciferase 
substrate colenterazine-h. Lodoxamide, pamoic acid and zaprinast were purchased from commercial sources. 
 
Analysis of drug targets and genetic association data. To assess how many receptors with more than one 
isoform are known GPCR drug targets, we used information on 474 FDA approved drugs matched to their 
GPCR targets as available in the literature36. In addition, we analysed phosphorylation sites annotated in 
reference isoforms were not retained in non-reference receptor isoforms by analysing data from 
PhosphoSitePlus64. To assess whether non-reference isoforms could be associated with clinical phenotypes of 
pharmacological interest, we analysed SNPs in the human population that were statistically significantly 
associated with phenotypes in the Gene ATLAS40 database. We considered only associations having high 
statistical significance (P < 1e-10) and involving clinically determined phenotypes (excluding self-reported and 
generic phenotypes). The resulting SNPs were then mapped to non-reference receptor isoform sequences. For all 
the analysed GPCRs, we only considered phenotype associations if they uniquely mapped to SNPs in the non-
reference isoform. Finally, we assessed which alternative isoforms could represent druggable targets and might 
offer isoform-level tissue selectivity. To do that, we used the multiple sequence alignments from the previous 
steps to filter for non-reference isoforms with a different sequence in at least one extracellular segment (i.e. in 
the N-terminus or ECL1, 2 or 3). We then filtered for non-reference isoforms with a different tissue distribution 
compared to the reference isoform using the previously computed receptor-centric binary expression matrices. 
To do so, we used the previously obtained binary tissue expression fingerprints (i.e. the strings of 1 (expressed) 
or 0 (not expressed) of length 30 corresponding to the 30 GTEx tissues) for each receptor isoform to select those 
non-reference isoforms with expression fingerprints that differed from their respective reference isoform. 
 
Mass spectrometry data analysis. We analysed the available mass spectrometry (MS) data on GPCR isoforms 
at the protein level by using a brain-derived MS dataset (PRIDE accession number: PXD0079985). Using these 
data, we mined for peptides uniquely matching one of the isoforms detected in brain tissue in the GTEx dataset. 
A total of 105 MS runs from brain tissue were used for identifying potential peptides associated with GPCR 
proteins (FDR	< 0.01 using the target-decoy strategy). Detailed parameters for database search were described 
in our recent publication65. In brief, all 105 MS/MS raw data files were searched against a composite 
target/decoy database66 using the JUMP hybrid search engine67. The target database was generated by 
combining the Swiss-Prot human core database (20,368 entries) and manually curated GPCR isoforms (1,033 
entries), and the decoy database was produced by reversing the target protein sequences. FDR was estimated by 
the number of decoy matches (nd) and the number of target matches (nt), according to the equation (FDR = 
nd/nt). Putative peptide-spectrum matches (PSM)s were filtered by mass accuracy and then grouped by 
precursor ion charge state and further filtered by JUMP scores (Jscore and ΔJn) to reach the expected FDR. All 
GPCR transcripts with two or more isoforms as detected in the GTEx brain tissue transcriptome dataset were 
filtered to obtain isoforms with unique protein sequences. These transcripts were then matched with the brain 
MS hits to identify receptor isoforms at the protein level. We also analysed data from an independent MS study 
consisting of 50 MS runs from 29 healthy human tissues48. Raw MS data were downloaded from the FTP site 
ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD010154. All 1,557 MS data files were searched against 
the same composite target/decoy database using the comet engine to increase search speed68. Major parameters 
included precursor mass tolerance (±10 ppm) and product ion mass tolerance (0.01 Da), full trypticity, dynamic 
mass shift for Met oxidation (+15.99491), maximal missed cleavage (n = 2), and maximal modification sites (n 
= 3). Putative PSMs were filtered by mass accuracy and comet scores (Xcorr and ΔCn) to reduce protein FDR < 
0.01. A total of 299,600 peptides were identified with FDR < 1%, including 4,182 peptides mapping to the 
detected GPCR isoforms. These peptides were then filtered to select only those that would uniquely 
discriminate a particular GPCR isoform by searching the previously obtained isoform sequences for unique hits. 
Finally, we used ProteomicsDB69 (www.proteomicsdb.org) to systematically explore all GPCRs for which more 
than one isoform had been detected using their REST API. To do that, we used isoform-specific Uniprot 
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identifiers to identify isoforms that had peptides uniquely matching to them (ISUNIQUE = 1).  
 
Cell line and single cell RNA expression analysis. We used RNA-seq data deposited in BioProject70 
(accession number PRJNA183192) to analyse the receptor transcripts expressed in 11 commonly used human 
cell lines (HEK293, SHSY5Y, RT-4, PC-3, MCF-7, Hep-G2, HeLa, CACO-2, A-549, U-251MG, and A-431) 
derived from 10 different human tissues. Following the analysis pipeline used for the GTEx transcript-level 
expression data, SRA files for all cell line experiments were downloaded and converted to FASTQ files with 
fastq-dump. Next, transcript level information was obtained with RSEM71 using the GRCh37 human assembly 
as a reference. GPCR transcripts expressed over the previously defined expression threshold (≥1 TPM) were 
considered for comparison. The same analysis was repeated for a single cell RNAseq dataset from healthy 
human pancreas49 (BioProject accession number PRJNA322355). SRA files for all single cell experiments were 
downloaded and converted to FASTQ files with fastq-dump. Again, transcript level information was obtained 
with RSEM71 using the GRCh37 human assembly as a reference. GPCR transcripts expressed over the 
previously defined expression threshold (≥1 TPM) were considered for comparison and grouped according to 
inferred cell types as annotated by the authors in BioProject. 
 
Data visualisation and analysis. All graphics were created using RStudio version 1.1.419 and the ggplot 
package as well as the UpSetR, ggalluvial and snakeplotter packages for their respective figures. Unless stated 
otherwise, all calculations, analyses and data processing were performed using custom written scripts in R. All 
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Figure 1. GPCR-wide analysis of isoform expression in humans. a, Alternative transcription start or termination, together 
with alternative splicing, can generate non-reference receptor isoforms (i.e. isoforms with different sequences than the 
GPCRdb annotated receptor), with altered structural and signalling properties. b, Analysis pipeline combining GTEx 
isoform-level data with GPCRdb, Ensembl, and UniProt annotations to filter for highly-expressed, protein-coding isoforms; 
isoforms with truncated signal peptides or those without at least one conserved transmembrane helix as compared to their 
















Figure 2. Structural diversity and functional impact of receptor isoforms. a, Annotation of multiple sequence 
alignments for all GPCRs with more than one isoform according to structural segment definitions in GPCRdb allows 
discriminating topologically preserved isoforms containing all the transmembrane (TM) segments present in the reference 
isoform (dark blue), and topologically truncated isoforms with at least one missing or altered TM segment (light blue). This 
information is used to generate a structural fingerprint for every receptor isoform. b, Distribution of abundance of unique 
structural fingerprints for receptors with two or more isoforms. Dark blue and light blue bars represent the abundance of 
topologically conserved and truncated versions of a structural fingerprint, respectively. Pie charts show the GPCR class 
distribution, as annotated in the IUPHAR/BPS the Guide To Pharmacology database (www.guidetopharmacology.org), in 
the three most common structural fingerprints. Asterisks indicate fingerprints with at least one functionally characterised 
receptor in the literature as shown in c, Association between structural fingerprints and functional impact as available in the 
literature. Receptors with functionally characterised isoforms are listed in black. Height of the individual stacked bars 
represents the number of characterised isoforms in the literature. Receptors listed in light grey have the same structural 












Figure 3. Tissue distribution of receptor isoforms and the impact of combinatorial isoform expression on 
pharmacological response. a, Relationship between the number of GPCRs expressed in the different GTEx tissues (left 
axis, grey line) and the mean number of isoforms per receptor expressed in each tissue (right axis, mean and standard error 
bars shown in black). b, Isoform expression matrix for the cannabinoid receptor 1 and Adhesion G protein-coupled receptor 
E2 (CNR1, CD97). Considering how many unique isoform combinations exist for a particular receptor across all GTEx 
tissues allows us to determine the number of receptor tissue expression signatures. The relationship between number of 
tissue expression signatures and the total number of isoforms per receptor is shown on the right. The dark grey regression 
line was obtained using a linear model and the light grey confidence interval represents the standard error. c, Tissue 
distribution of the reference (grey) and the two topologically conserved CNR1 non-reference isoforms (purple and green) 
with changes in the N-terminus (see alignment in Extended Fig. 5a). d, Top right inset: Schematic representation of CNR1-
mediated inhibition of cAMP production by adenylate cyclase (AC). Pharmacological modulation can be attained by AC 
activation by Forskolin (Fsk) or CNR1 inverse agonism by Rimonabant. Representative trace of mean cAMP levels in Fsk 
(5µM)-stimulated HEK 293 cells expressing FLAG-tagged CNR1 reference isoform along with SNAP-tagged reference 
isoform as a control or SNAP-tagged non-reference isoform1 or isoform 2. e, Endpoint cAMP levels are significantly 
decreased in cells co-expressing the reference isoform and non-reference isoform1 compared to cells expressing only the 
reference isoform. f, Total cAMP response, normalized to cells expressing the reference isoform, is increased in cells co-
expressing the reference isoform and non-reference isoform2 compared to the control cells (ref+ref, n=23 cells; ref+iso1, 
n=18 cells; ref+iso2, n=27 cells; by one-way ANOVA with Dunnett’s multiple comparisons test). Box plots show 10-90th 
percentile with the median, 25th, and 75th percentile as well as the mean (+). Individual data points are overlaid on the box 
plot. g, Heatmap representation of cAMP levels after Fsk and Rimonabant treatment over time in individual HEK 293 cells 
expressing a Flag-tagged reference isoform and the different SNAP-tagged isoforms. CFP/FRET ratios were normalised 
using the baseline ratio as 0 and the maximum ratio after Fsk, but before Rimonabant, treatment as 1. h, Tissue distribution 
of the reference (grey) and the GIPR non-reference isoform 1 with changes in the C-terminal segment (pink) (see alignment 
in Extended Fig. 5i). i, Radar plots summarising differences in potency (ΔpEC50) and maximum response (ΔEmax) for 4 
different measurements (cAMP and intracellular calcium (Ca2+)i release, and β-arrestin 1 and 2 recruitment) between cells 














































Figure 4. GPCR isoforms of drug targets. a, Number of receptors categorized by the number of tissue expression 
signatures for all GPCRs (grey) and for those which belong to the 111 targets of 474 FDA-approved drugs (in green). b, 
Filtering based on structural and expression considerations identifies non-reference isoforms with extracellular structural 
changes and tissue distribution that is different from the reference isoform, potentially allowing the development of ligands 
that specifically target them. c, Tissue distribution of the reference and isoform 1 of GPR35. BRET signals were monitored 
after treatment of HEK-293T cells with varying concentrations of lodoxamide, pamoic acid, and zaprinast using a GPR35-
Gα13 SPASM sensor (upper panel; n=3) or eYFP-tagged GPR35 isoforms and β-arrestin 2 tagged with Nanoluciferase 
(lower panel; n=3, see Methods for further details). 
 
 
Figure 5. From a canonical to a context-specific view of GPCR signalling. Integration of multiple datasets provides an 
isoform-centric view of GPCR signalling. In the case of receptors with a single isoform, activation by a particular ligand 
concentration will result in an observed signalling readout. However, when receptors have multiple isoforms expressed in 
the same system, a signalling readout may be the collective result of activating structurally and pharmacologically distinct 
receptor isoforms. If the isoform composition changes in different systems (s1 to sn), this can result in differences in 
signalling in response to the same ligand (left, right; intensity of the box denotes extent of signalling response). The different 
systems can correspond to different levels of complexity from that of a single cell, to tissues, and entire organisms. In this 
manner, combinatorial expression of functionally distinct GPCR isoforms can diversify receptor signalling response.  
